Tobacco Control

Share

Tobacco products are projected to kill one billion people worldwide this century. And the industry is showing no signs of slowing down, spending more than $9 billion on marketing each year. 

Despite the industry's deceptive and deadly practices, ACS CAN continues to have enormous success passing local, state and federal laws that prevent children from smoking, help adults quit and ensure the government uses its authority to regulate tobacco industry practices.

While our work has had an enormous impact on youth cigarette use - now at historic lows - the use of e-cigarettes among kids is skyrocketing.  This further reinforces the importance of continuing this lifesaving work.

Take Action

Protect our Children from Big Tobacco

The tobacco industry has preyed upon young people by marketing products that appeal to kids.

Latest Updates

April 15, 2025
Indiana

Today, the Indiana legislature passed the budget, sending it to the conference committee. Unfortunately, this version of the budget does not include increased tobacco taxes or funding for programs that help prevent tobacco use and help those already addicted quit.

April 11, 2025
West Virginia

West Virginia Can and Must Do Better When It Comes to Reducing Tobacco Use

April 9, 2025
Ohio

Ohio Can and Must Do Better When It Comes to Reducing Tobacco Use

April 8, 2025
Maryland

Maryland state lawmakers have released details on the agreed upon 2025-26 budget—the contents of which are a mixed bag in the fight against cancer. While the state made sound investments in cancer research and protected Medicaid recipients’ ability to access biomarker testing, it missed an opportunity to save the lives and lungs of Maryland’s youth by cutting funding for the state’s tobacco prevention and cessation programs.

Tobacco Control Resources

Whether Puff Bar is under the jurisdiction of the Center for Drug Evaluation and Research
(CDER) as a drug or the Center for Tobacco Products (CTP) as a tobacco product, it is critical that
FDA take action and not permit this company and this product to escape regulatory oversight.
Puff Bar has neither been approved as a drug nor received a premarket tobacco product order.
The agency should not allow any perceived regulatory “gap” to enable this company or any
other company to market new addictive nicotine products without going through the legally
required FDA review by either CDER or CTP.

Because JUUL’s products continue to have the largest share of the e-cigarette market, and therefore presumably are undergoing expedited review, we write at this time to express our conclusion that based on all of the publicly available evidence, no JUUL product currently on the market can meet the statutory public health standard. Therefore, they should not receive a marketing order.